Viking Therapeutics Stock Analysis: Growth Narrative Remains Compelling
Viking Therapeutics (NASDAQ: VKTX) is once again a focal point for investors following its recent price movement. While shares experienced notable weakness in the last U.S. trading session, the underlying clinical data for its lead drug candidate, VK2735, continues to present a robust outlook. A key consideration for investors is the distinct profile of the candidate’s two delivery methods: an injectable formulation and an oral tablet.
During early European trading, the stock traded around €29.50 on German exchanges, reflecting the prior session’s decline on the NASDAQ. On Friday, shares closed at $32.22, marking a decrease of $1.87, or 5.49%.
Several key metrics provide context for the current valuation:
- Previous U.S. Close:…
